Lophius Biosciences GmbH Signs Agreement With BL&H Co. Ltd. For T-Track CMV In Korea
(Regensburg, 25.06.2015) Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell based research tools and diagnostic systems for functional assessment of pathogen/disease-reactive T cells, today announced an exclusive sales and marketing distribution agreement with BL&H Co. Ltd. for sale of its T-Track® CMV diagnostic kit in Korea.
Under the terms of the agreement BL&H Co. Ltd. will exclusively market and sell T-Track® CMV to the transplantation centers following the approval of the diagnostic assay by the Korean Ministry of Food and Drug Safety. The distribution deal includes milestone payments to Lophius. T-Track® CMV is currently sold for research purposes and is expected to be available as an in vitro diagnostic (IVD) in Korea by the end of 2016.
The T-Track® CMV assay is a diagnostic test for the measurement of CMV-specific cell mediated immunity based on the ELISpot method combined with the T-activation® Technology. Lophius T-Track® CMV represents a highly standardized and sensitive diagnostic tool to assess the functionality of a network of clinically relevant CMV-reactive effector cells. It is based on the stimulation of peripheral blood mononuclear cells (PBMC) with T-activated® immunodominant CMV proteins, pp65 and IE-1, and the subsequent quantification of CMV-specific CMI using a highly sensitive IFN-gamma ELISpot.
Dr. Robert Phelps, CEO of Lophius Biosciences comments "We are very excited to collaborate with such a strong distribution partner in Korea. BL&H has more than 15 years of experiences in supporting patients with hospital-based services and products. This has allowed the company to foster strong and lasting relationships with both the reference laboratories performing the tests, and key opinion leaders applying the information from the results. We therefore believe that BL&H is an ideal partner to provide T-Track® CMV to transplant patients in Korea."
Mr. D. C. Roh, president of BL&H said "With the introduction of T-Track® CMV, I am pleased that we will be able to offer an exciting new option for assessment of the functionality of CMV-reactive effector cells to use anti viral therapy more effectively. We are looking forward to its successful introduction to the market. Our partnership with Lophius Biosciences will make a valuable contribution to the improvement of the quality of life of patients in Korea."
About BL&H
BL&H is a privately owned Korean pharmaceutical company, established in 1999, with the aim of becoming a leader in the delivery of pharmaceuticals and services that fulfill unmet medical needs of the Korean market. BL&H specializes in hospital-based products in hematology and oncology. BL&H's management team has extensive experiences in the pharmaceutical and healthcare sector and brings specialist products to these markets.
Help employers find you! Check out all the jobs and post your resume.
Under the terms of the agreement BL&H Co. Ltd. will exclusively market and sell T-Track® CMV to the transplantation centers following the approval of the diagnostic assay by the Korean Ministry of Food and Drug Safety. The distribution deal includes milestone payments to Lophius. T-Track® CMV is currently sold for research purposes and is expected to be available as an in vitro diagnostic (IVD) in Korea by the end of 2016.
The T-Track® CMV assay is a diagnostic test for the measurement of CMV-specific cell mediated immunity based on the ELISpot method combined with the T-activation® Technology. Lophius T-Track® CMV represents a highly standardized and sensitive diagnostic tool to assess the functionality of a network of clinically relevant CMV-reactive effector cells. It is based on the stimulation of peripheral blood mononuclear cells (PBMC) with T-activated® immunodominant CMV proteins, pp65 and IE-1, and the subsequent quantification of CMV-specific CMI using a highly sensitive IFN-gamma ELISpot.
Dr. Robert Phelps, CEO of Lophius Biosciences comments "We are very excited to collaborate with such a strong distribution partner in Korea. BL&H has more than 15 years of experiences in supporting patients with hospital-based services and products. This has allowed the company to foster strong and lasting relationships with both the reference laboratories performing the tests, and key opinion leaders applying the information from the results. We therefore believe that BL&H is an ideal partner to provide T-Track® CMV to transplant patients in Korea."
Mr. D. C. Roh, president of BL&H said "With the introduction of T-Track® CMV, I am pleased that we will be able to offer an exciting new option for assessment of the functionality of CMV-reactive effector cells to use anti viral therapy more effectively. We are looking forward to its successful introduction to the market. Our partnership with Lophius Biosciences will make a valuable contribution to the improvement of the quality of life of patients in Korea."
About BL&H
BL&H is a privately owned Korean pharmaceutical company, established in 1999, with the aim of becoming a leader in the delivery of pharmaceuticals and services that fulfill unmet medical needs of the Korean market. BL&H specializes in hospital-based products in hematology and oncology. BL&H's management team has extensive experiences in the pharmaceutical and healthcare sector and brings specialist products to these markets.
Help employers find you! Check out all the jobs and post your resume.